Recombinant Newcastle disease virus as a vaccine vector for cancer therapy

Area of Science:

• Oncolytic virotherapy
• Immunotherapy
• Virology
• Cancer research

Background:

• Naturally occurring Newcastle disease virus (NDV) strains are under investigation for oncolytic cancer therapy.
• Previous research established recombinant NDVs engineered for enhanced therapeutic efficacy.
• NDV expressing interleukin-2 (IL-2) demonstrated a robust therapeutic response via increased tumor-specific T-cell infiltration.

Purpose of the Study:

• To confirm the T-cell dependency of the therapeutic response induced by NDV-IL-2.
• To investigate focusing the NDV-induced immune response toward a tumor-associated antigen (TAA) for enhanced efficacy.
• To evaluate the combined effect of NDV-TAA and NDV-IL-2 in cancer therapy.

Main Methods:

• Development of recombinant NDVs expressing a model tumor-associated antigen (TAA).
• Intratumoral administration of recombinant NDVs in tumor-bearing mice.
• Evaluation of therapeutic response, including complete tumor regressions and T-cell infiltration.

Main Results:

• Recombinant NDV expressing a TAA elicited an enhanced tumor-specific response, leading to significantly more complete tumor regressions than control NDV.
• The therapeutic response to NDV-IL-2 was confirmed to be T-cell dependent.
• Coadministration of NDV-TAA and NDV-IL-2 further enhanced the TAA-directed response and increased complete tumor regressions.

Conclusions:

• Oncolytic recombinant NDV engineered to express TAAs can enhance tumor-specific immune responses.
• Combining TAA-directed immunotherapy with IL-2-expressing NDV significantly improves therapeutic efficacy.
• TAA-directed immunotherapy using oncolytic recombinant NDV, alone or in combination with IL-2, warrants consideration for cancer therapy development.